Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) EBIT (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of EBIT data on record, last reported at $583.2 million in Q4 2025.

  • For Q4 2025, EBIT rose 369.6% year-over-year to $583.2 million; the TTM value through Dec 2025 reached -$237.6 million, up 65.55%, while the annual FY2025 figure was -$237.6 million, 65.55% up from the prior year.
  • EBIT reached $583.2 million in Q4 2025 per RVMD's latest filing, up from -$315.3 million in the prior quarter.
  • Across five years, EBIT topped out at $583.2 million in Q4 2025 and bottomed at -$315.3 million in Q3 2025.
  • Average EBIT over 5 years is -$93.0 million, with a median of -$92.7 million recorded in 2022.
  • Peak YoY movement for EBIT: crashed 191.67% in 2023, then soared 369.6% in 2025.
  • A 5-year view of EBIT shows it stood at -$52.9 million in 2021, then dropped by 16.62% to -$61.7 million in 2022, then plummeted by 191.67% to -$180.0 million in 2023, then dropped by 20.18% to -$216.3 million in 2024, then skyrocketed by 369.6% to $583.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $583.2 million in Q4 2025, -$315.3 million in Q3 2025, and -$264.7 million in Q2 2025.